This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

PATENT/Docket No.: 00118.US1

Serial No.: 09/992,660

Page No. 1

CERTIFICATE OF MAILING (37 CFR 1.8)	
Date of Deposit with U.S. Postal Service:	1, 2002
I hereby certify that this paper is being deposited wit under 37 CFR 1.8 on the date indicated above and is Trademarks, Washington D.C. 20231.	h the United States Postal Service as first class mail addressed to the Commissioner of Patents and
Julie K. Lyons, Legal Assistant	reliek Lyons
Name of Person Mailing Paper	Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1626

Examiner

Unknown

Applicant(s)

Paul D. Johnson, Paul A. Aristoff, Toni-Jo Poel, Lisa M. Thomasco

Serial No.

09/992,660

Filed

November 14, 2001

For

Oxazolidinones Having a Benzannulated 6- or 7- Membered Heterocycle

Commissioner of Patents and Trademarks Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL UNDER 37 CFR 1.97 AND 1.98

Sir:

Information Disclosed. The information disclosed consists of the following:

- [X] Form PL-1449. Provided herewith are copies of patent(s) and/or publication(s) as listed in the attached form PL-1449.
 - [X] At least to the extent required under §1.98(a)(3), a concise explanation of the relevance of references listed in form PL-1449 is:

[X] contained in the above-captioned specification as filed;

[] provided in a communication enclosed with this paper;

[] provided in the International Search Report enclosed with this paper; and/or

[] not necessary as all of the references cited are in the English language.

PATENT/Docket No.: 00118.US1

Serial No.: 09/992,660

Page No. 2

[] Disclosure from Predecessor Application. Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.53(d)) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, Serial No. filed , the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).

Basis for Consideration. This information disclosure statement is entitled to consideration by the Office under:

§1.97(b), as being filed within three months of the filing date of the above-captioned

application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is/are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below. §1.97(c), as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311. Consideration of this information disclosure statement at this time is requested for the reason checked below: Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$240.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account. [] A statement as specified in 37 CFR 1.97(e) below. [] §1.97(d), as being filed after the period specified in §1.97(c), but on or before payment of the issue fee and is accompanied by: Authorization to charge Deposit Account No. 21-0718 the fee set forth in §1.17(i), \$130.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account. [] A petition requesting consideration of the information disclosure statement; and

A statement as specified in 37 CFR 1.97 (e) below.

§1.97(e), this is a supplemental information disclosure statement. A prior

information disclosure statement has already been filed. Applicant certifies, as provided

[]

in 37 CFR 1.97 (e), that

[X]

PATENT/Docket No.: 00118.US1

Serial No.: 09/992,660

Page No. 3

Each new item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

[] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing below, after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this statement.

Date: 4-10-02

Disclaimer. In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,

Jonathan P. O'Brien, Patent Agent

Registration No. 50,852

Pharmacia & Upjohn Company Global Intellectual Property 301 Henrietta Street Kalamazoo, Michigan 49001

Telephone No. (616) 833-2102 or (616) 833-9500 Telefax No. (616) 833-8897 or (616) 833-2316

Attachment(s)

[X] Form 1449 with copies of reference(s)

Form 1449 from predecessor application (no references) []

[] Communication providing concise explanation of relevance

[] International Search Report

		•							
			Atty. Docket No.			Serial No			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		00118.US1		09/992,660					
				Applicant Paul D. Johnson, Paul A. Aristoff, Toni-Jo Poel, Lisa M. Thomasco					
İ			Filing Date	Group 1626					
							November 14, 2001		
			U.S. PA	ATENT DOCUMENTS		1			
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		
	AA	5,164,510	Nov. 17, 1992	SJ Brickner	548	231	Feb. 20	, 1991	
	AB								
	AC								
	AD						7.		
	AE								
	AF								
	AG								
	AH								
	AI			,					
			- FOREIGN	PATENT DOCUMENTS					
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
	AJ	WO 96/05194	22 Feb. 1996	WIPO	C07D	403/04		x	
	AK	WO 99/64416	16 Dec. 1999	WIPO	C07D	413/14	х		
	AL	WO 99/64417	16 Dec. 1999	WIPO	C07D	413/14	x		
	AM	WO 00/10566	2 March 2000	WIPO	A61K	31/42	х		
	AN	WO 00/21960	20 April 2000	WIPO	C07D	413/14	х		
	BJ	WO 00/73301	7 Dec. 2000	WIPO	C07D	413/04	Х		
			OTHER PRIOR ART (Inc	cluding Author, Title, Date, Pertinent	Pages, Etc.)				
	AO	M. Carmack, "T [1989];	ne Willgerodt-Kindler Re	eactions. 7. The Mechanisms,	J. Hetero	cyclic Chem.	, 26:1319	-1323	
	AP	B. Pecherer; Sunbury, R.C.; and A. Brossi, "The Synthesis of Some 7- and 7,8-Substituted 2,3,4,5-Tetrahydro-1 <i>H</i> -3-benzazepines," J. Heterocyclic Chem. 779-783 [1971];							
	AQ	J. David Margerum; and C.T. Petrusis, "The Photodecarboxylation of Nitrophenylacetate Ions," J. Amer. Chem. Society 91:2467-2472 [1969];							
	AR			A Simple One-Step Conversi rate (TTN)," J. Amer. Chem.				ì	

Serial No. 09/992,660			
Applicant Paul D. Johnson, Paul A. Aristoff, Toni-Jo Poel, Lisa M. Thomasco			
oup 1626			
sis of 1,2,3,4- 3:4116-4119 [1998];			
mic Kinetic Resolution of Epichlorohydrin via Enantioselective Practical Synthesis of Aryl Oxazolidinone Antibacterial Agents," [1996].			
_			